GW Pharmaceuticals Announces Preliminary Topline Results from Phase 2a Ulcerative Colitis Trial

Click here to receive IBD news via e-mailthe results

the resultsGW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing new therapeutics from its cannabinoid product platform and that commercialized the world’s first plant-derived cannabinoid prescription drug Sativex® for spasticity (rigid muscles), recently presented the preliminary top line results from a Phase 2a ulcerative colitis trial at their ResearchDevelopment event in New York City.

The Phase 2a ulcerative colitis trial was a 10-week randomized, double-blind, placebo controlled study of the GWP42003 extract, which contains Cannabidiol (CBD) as the main cannabinoid, Tetrahyrdocannabinol (THC), and other cannabinoid and non-cannabinoid components. This study enrolled 60 adult patients with ulcerative colitis without remission from the condition, despite having been treated with a first line therapy, such as salicylates and, in some cases, immunosuppressive drugs.  The patients were

... read more at: http://ibdnewstoday.com/2014/11/07/gw-pharmaceuticals-announces-preliminary-topline-results-from-phase-2a-ulcerative-colitis-trial/

by